Pharmaceutical Industry Articles & Reports - Page 6

A 2026 analyst guide to AI documentation for skilled nursing facilities, covering MDS/PDPM coding assistants, AI scribes, CDI tools, HIPAA compliance, and peer-reviewed evidence on accuracy and ROI.

A July 2026 comparison of Claude Science, GPT-Rosalind, and Isomorphic Labs covering pricing, access models, published benchmarks, named enterprise adoption, and which platform fits which life-sciences use case.

A 2026 analyst comparison of ChatGPT and Claude for healthcare covering HIPAA and BAA compliance, pricing tiers, MedQA and HealthBench accuracy data, and five named hospital case studies.

2026 guide to the ChatGPT Enterprise BAA: which plans qualify for HIPAA coverage, the ~$60/seat, 150-seat pricing pattern, how to request a BAA, and vendor comparisons with Microsoft, Google, and Anthropic.

A 2026 analyst guide to de-identifying clinical notes for LLM analytics: HIPAA Safe Harbor vs Expert Determination, NER tool benchmarks for Presidio, Philter, and John Snow Labs, and re-identification risk data.

A 2026 data report on data center GPU pricing: verified H100, H200, B200, and GB200 NVL72 rental and purchase costs across 20+ cloud providers, plus capex and shortage trends.

Compares HIPAA compliance and BAA availability for ChatGPT, Claude, Microsoft Copilot, and Gemini plus clinical AI scribes like Abridge and Nabla, with 2026 pricing, KLAS survey data, and OCR enforcement cases.

A 2026 analyst guide to AI for prior authorization appeals, covering letter templates, ChatGPT prompts, tool comparisons like Claimable and Counterforce Health, denial statistics, and state AI laws.

A July 2026 analyst report on Kimi K3 for life sciences: Moonshot's 2.8T open-weight model, HIPAA and GxP deployment paths, China cross-border data risk, and self-hosting reality.

A 2026 analyst report on Chai Discovery's $400M Series C at a $3.8B valuation, covering Chai-3 benchmarks, Lilly, Pfizer, Novartis, and argenx deals, and AI drug discovery megaround trends.

A 2026 compliance analysis of whether life sciences companies can use DeepSeek, Kimi K2/K3, and Qwen, covering GDPR, the US Bulk Data Transfer Rule, PIPL, HIPAA, and FDA AI guidance.

A 2026 guide to what counts as protected health information under HIPAA when using AI tools, covering the 18 Safe Harbor identifiers, Expert Determination, BAA coverage for ChatGPT and Claude, and enforcement cases.

A 2026 guide to the FDA's AI-enabled medical device list: 1,524 entries reviewed this session, 510(k) versus De Novo pathways, radiology's 76 percent share, JAMA Health Forum evidence gaps, and landmark clearances including LumineticsCore and Aidoc CARE.

2026 analyst comparison of Kimi K3 vs Claude Fable 5, GPT-5.6, and Gemini 3.1 Pro covering per-token API pricing, GDPval-AA v2 benchmarks, open-source licensing status, and enterprise adoption cases.

A 2026 analyst comparison of Suki, Nuance DAX (Dragon Copilot), Abridge, and Freed covering pricing, KLAS rankings, Epic and Cerner integration, HIPAA compliance, and peer-reviewed accuracy data.

A 2026 guide to whether ChatGPT is HIPAA compliant, covering OpenAI's BAA process, the new ChatGPT for Healthcare product, Azure/Google/AWS alternatives, and HIPAA penalties up to $2.19 million per violation.

Analyzes the July 2026 Insilico Medicine and Bora Pharmaceuticals $2.5 billion alliance: deal structure, AI-in-CDMO manufacturing shift, AI literacy mandates, and 2026 market data.

Analyst breakdown of the July 2026 Samsung Bioepis-Proteina AI antibody deal: the option contract structure, SPID scoring, RosettaFold-lineage AbGPT-3D design AI, and comparisons to Jazz-AbCellera and Celltrion-Galux.

Analyzes whether AI has discovered any FDA-approved drugs as of 2026, covering Insilico Medicine's rentosertib Phase III trial, Takeda's zasocitinib, clinical success rates, and billions in AI drug discovery investment.

Analysis of Novartis's 2026 up to $1.5B acquisition of Myricx Bio, covering the NMTi ADC payload platform, B7-H3/HER2/TROP2 pipeline, deal terms, leadership, and biopharma M&A context.

A 2026 data-driven playbook for AI adoption in biotech covering Bain, ZS, KPMG, and Deloitte survey data, change-management frameworks, training programs, and named cases from Moderna, AstraZeneca, Pfizer, and Insilico Medicine.

A 2026 compliance guide to ChatGPT in medical offices: which tiers require a signed BAA, HIPAA penalties up to $2.19 million per violation, and HIPAA-ready alternatives like Claude for Healthcare and Doximity.

A 2026 analyst breakdown of whether Claude is HIPAA compliant: which plans support a signed BAA, what Claude Enterprise and the API actually cover, and how Claude compares to ChatGPT, Copilot, and Gemini.

How medical practices build a HIPAA compliant AI use policy in 2026, covering PHI rules, Texas/California/Illinois/Colorado disclosure laws, governance steps, and free templates from CHCANYS, HFMA, and MAIN.